Search results
Showing 1351 to 1365 of 2006 results for nice guidelines
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
This guidance has been updated and replaced by NICE guideline CG178. This guideline updates and replaces NICE guideline CG1.
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)
This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.
This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)]
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
This guidance has been updated and replaced by NICE guideline NG192 and the recommendations on multiple pregnancy have been updated and replaced by NICE guideline NG137.
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Temperature control to improve neurological outcomes after cardiac arrest (HTG710)
Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).
View recommendations for HTG710Show all sections
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .